Search results for "F-18"

showing 6 items of 6 documents

Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy

2017

Abstract Background: To assess the long-term prognostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with differentiated thyroid carcinoma (DTC) undergoing empiric radioiodine (RAI) therapy due to raising values of thyroglobulin (Tg). Methods: Forty-nine patients with histological diagnosis of DTC (31 with papillary and 18 with follicular carcinoma) follow-up for a mean period of 7.9 ± 5 years after empiric RAI therapy were retrospectively analyzed. Results: FDG-PET/CT was negative in 15 (30.6%) patients and positive in 34 (69.4%), whereas postradioiodine therapy whole body scan (t-WBS) was negative in 16 (32.7%) and positive in…

AdultMalemedicine.medical_specialtymedicine.medical_treatment18F-FDG-PET/CTchemistry.chemical_elementIodinethyroglobulinDiagnostic Accuracy StudyDisease-Free Survival030218 nuclear medicine & medical imagingThyroid carcinomaIodine Radioisotopes03 medical and health sciences0302 clinical medicineFluorodeoxyglucose F18Positron Emission Tomography Computed TomographymedicineHumansThyroid NeoplasmsThyroid cancerdifferentiated thyroid carcinomaAgedRetrospective Studies18F-FDG-PET/CT differentiated thyroid carcinoma empiric therapy prognosis thyroglobulin4300medicine.diagnostic_testbusiness.industryRetrospective cohort studyempiric therapyGeneral MedicineMiddle Agedmedicine.diseasechemistryPositron emission tomography030220 oncology & carcinogenesisF-18-FDG-PETHistopathologyThyroglobulinFemaleRadiologyprognosisRadiopharmaceuticalsNuclear medicinebusinessEmpiric therapyCTResearch Article
researchProduct

Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET

2015

Dopamine D2/3 receptor (D2/3R) agonist PET tracers are better suited for the imaging of synaptic dopaminergic neurotransmission than D2/3R antagonists and may also offer the opportunity to study in vivo the high-affinity state of D2/3R (D2/3RHigh). With the aim to develop 18F-labeled D2/3R agonists suitable for widespread clinical application, we report here on the synthesis and in vitro and in vivo evaluation of a D2/3R agonist ligand from the aminomethyl chromane (AMC) class-(R)-2-[(4- 18Fluorobenzylamino)methyl]chroman-7-ol (18F-AMC20). Methods: In vitro affinities of AMC20 toward dopaminergic receptor subtypes were measured in membrane homogenates prepared from HEK293 cells expressing h…

MaleBenzylaminesChemistry Techniques SyntheticPharmacologyLigandsRats Sprague-DawleyCricetinaeBINDINGRadioligandIN-VIVORacloprideRadiochemistryChemistryDopaminergicBrainStereoisomerismLigand (biochemistry)SERIESADDICTIONDopamine receptorDopamine AgonistsHIGH-AFFINITY STATEmedicine.drugAgonistmedicine.drug_classDRUG-ABUSECHO CellsPOSITRON-EMISSION-TOMOGRAPHYCricetulusFIn vivoDopamine receptor D2medicineAnimalsHumansRadiology Nuclear Medicine and imagingBenzopyransChromansReceptors Dopamine D2F-18Receptors Dopamine D3Biological TransportAgonist tracerRatsKineticsHEK293 CellsPETDopamine receptorRaclopridePositron-Emission TomographyRADIOTRACERSYSTEMJournal of Nuclear Medicine
researchProduct

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

Metabolic Response Assessment in Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A Preliminary Analysis

2015

The purpose of this study was to evaluate the clinical value of PET (Positron Emission Tomography) for early prediction of tumor response to platinum-based therapy in patients with nonsmall cell lung cancer (NSCLC). The evaluation was carried out comparing the standard treatment response using RECIST (Response Evaluation Criteria in Solid Tumors) with metabolic treatment response according to European Organization for Research and Treatment of Cancer (EORTC) recommendations, PET Response Criteria in Solid Tumors (PERCIST), Total Lesion Glycolysis (TLG) and Metabolic Tumor Volume (MTV). Seventeen inoperable patients with stage IV NSCLC were enrolled between October 2011 and June 2013: PET st…

Oncologymedicine.medical_specialtybusiness.industryF-FDG PETmedicine.disease18 F-FDG PET EORTC Non-small cell lung cancer PERCIST RECIST Therapy MonitoringPreliminary analysisResponse assessmentEORTCNon-small cell lung cancerRECISTTherapy MonitoringInternal medicinemedicineF-18-FDG PETRadiology Nuclear Medicine and imagingTherapy monitoringRadiologyNon small cellLung cancerbusinessPERCIST
researchProduct

The study of myocardial viability after myocardial infarction: Valve and limitations of magnetic resonance imaging compared with myocardial scintigra…

1997

International audience; Abstract: The aim of this study was to compare myocardial thickness measured by magnetic resonance imaging and quantified fixation of thallium. Twenty-one patients 61.2+/-11 years were investigated after myocardial infarction of the anterior wall in 8 cases, inferior in 10 cases, lateral in 2 cases and apical in one case. The mean angiographic ejection fraction was 46.5 +/- 19 %. Myocardial scintigraphy was performed after an exercise or pharmacological stress test and followed by a study of redistribution. The data was analysed by a quantitative method. Magnetic resonance imaging was performed with Vertical and horizontal long axis views in systole and diastole with…

VIABLE MYOCARDIUMF-18 FLUORODEOXYGLUCOSELEFT-VENTRICULAR DYSFUNCTION[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingCORONARY-ARTERY DISEASEPOSITRON EMISSION TOMOGRAPHYTL-201[INFO.INFO-IM]Computer Science [cs]/Medical Imaging[INFO.INFO-IM] Computer Science [cs]/Medical ImagingTHALLIUM UPTAKEREVASCULARIZATIONREINJECTIONIRREVERSIBLE DEFECTS
researchProduct

Multiparametric 18F-FDG PET-MRI of the breast: are there differences in imaging biomarkers of contralateral healthy tissue between patients with and …

2019

The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion c…

medicine.medical_specialtyImaging biomarkerdiffusion-weighted imagingMalignancy030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerF-18-FDG PET/MRImedicineMammographyEffective diffusion coefficientF-18-FDG PET/MRI breast cancer; dynamic contrast-enhanced MRI diffusion-weighted imaging imaging biomarkerimaging biomarkerRadiology Nuclear Medicine and imagingdynamic contrast-enhanced MRImedicine.diagnostic_testbusiness.industryCancermedicine.disease030220 oncology & carcinogenesisDynamic contrast-enhanced MRIRadiologybusinessDiffusion MRI
researchProduct